Fifteen students in the MD-PhD program at the Jacobs School of Medicine and Biomedical Sciences presented posters at the Tri-Institutional MD-PhD Research Day last fall at the Jacobs School building in downtown Buffalo.
Atrophied brain lesion volume is the only marker from MRI scans that can accurately predict which patients will progress to the most severe form of multiple sclerosis (MS), according to a retrospective, five-year study of 1,314 MS patients.
The PhD Program in Biomedical Sciences (PPBS) conducted its third annual white coat ceremony to recognize 19 students from the Class of 2018-2019 — 14 doctoral students and five MD-PhD students — who completed their first year in the program and are moving on to their research laboratory match.
New stem cell research led by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology, has identified novel therapeutic targets for the treatment of multiple sclerosis (MS) and other inflammatory diseases.
A preclinical study conducted by researchers in the Department of Pharmacology and Toxicology has shown for the first time that a class of proteins are important in the neurobiology of relapse or drug-seeking behaviors.